Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 16/20 | 0.52 |
| ▸ | DDB1 | Q16531 | 14/20 | 0.52 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | TNF | P01375 | 1/20 | 0.46 |
| ▸ | IL1B | P01584 | 1/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.46 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23267590 | 0.91 | CRBN (0.60) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL22276613 | 0.91 | CRBN (0.60) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL25518501 | 0.91 | CRBN (0.60) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL23705654 | 0.86 | CRBN (0.65) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL29617032 | 0.86 | CRBN (0.65) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL20133102 | 0.86 | CRBN (0.56) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL20133114 | 0.86 | CRBN (0.58) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL24459261 | 0.86 | CRBN (0.68) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL30862211 | 0.86 | CRBN (0.68) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL20133175 | 0.85 | CRBN (0.57) | CRBNDDB1IKZF3ALDH1A1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552775-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20240101534-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-03-28 | — | — | US | disclosed |
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-02 | — | — | US | disclosed |
| EP-4247815-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2023-09-27 | — | — | EP | disclosed |
| EP-4097096-A2 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
| WO-2022109396-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| WO-2022109396-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| WO-2021155321-A2 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| WO-2021155321-A2 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2021-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101534-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, BRCA1 | CRBN 163/4885DDB1 576/4885IKZF3 1199/4885 |
| US-12552775-B2 | Compounds and uses thereof | SMARCC1, SMARCC2, CHD1 | CRBN 125/4885DDB1 484/4885IKZF3 614/4885 |
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, BRCA1 | CRBN 163/4885DDB1 576/4885IKZF3 1199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.